VestGen Advisors LLC Has $7.09 Million Position in CME Group Inc. $CME

VestGen Advisors LLC grew its position in CME Group Inc. (NASDAQ:CME) by 2.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,735 shares of the financial services provider’s stock after purchasing an additional 672 shares during the period. VestGen Advisors LLC’s holdings in CME Group were worth $7,093,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Webster Bank N. A. lifted its holdings in CME Group by 206.9% during the second quarter. Webster Bank N. A. now owns 89 shares of the financial services provider’s stock worth $25,000 after acquiring an additional 60 shares in the last quarter. Highline Wealth Partners LLC raised its position in shares of CME Group by 84.3% during the second quarter. Highline Wealth Partners LLC now owns 94 shares of the financial services provider’s stock worth $26,000 after purchasing an additional 43 shares during the period. Ransom Advisory Ltd acquired a new stake in shares of CME Group during the first quarter worth about $31,000. Trifecta Capital Advisors LLC lifted its stake in CME Group by 59.2% in the second quarter. Trifecta Capital Advisors LLC now owns 113 shares of the financial services provider’s stock valued at $31,000 after buying an additional 42 shares in the last quarter. Finally, Westside Investment Management Inc. increased its position in shares of CME Group by 105.0% during the second quarter. Westside Investment Management Inc. now owns 123 shares of the financial services provider’s stock worth $34,000 after acquiring an additional 63 shares in the last quarter. Institutional investors and hedge funds own 87.75% of the company’s stock.

Insider Activity

In other news, Director William R. Shepard bought 262 shares of the company’s stock in a transaction dated Thursday, September 25th. The shares were bought at an average cost of $265.19 per share, with a total value of $69,479.78. Following the acquisition, the director owned 258,459 shares in the company, valued at $68,540,742.21. This trade represents a 0.10% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Jonathan L. Marcus sold 392 shares of CME Group stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $262.00, for a total value of $102,704.00. Following the transaction, the general counsel owned 7,851 shares of the company’s stock, valued at $2,056,962. The trade was a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,147 shares of company stock valued at $562,079 in the last 90 days. 0.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CME. Keefe, Bruyette & Woods upped their target price on shares of CME Group from $283.00 to $287.00 and gave the stock a “market perform” rating in a research note on Monday, October 13th. UBS Group dropped their price target on CME Group from $285.00 to $280.00 and set a “neutral” rating on the stock in a research note on Thursday, October 23rd. The Goldman Sachs Group boosted their target price on CME Group from $263.00 to $264.00 and gave the company a “sell” rating in a research note on Tuesday, November 25th. Argus decreased their price target on shares of CME Group from $308.00 to $295.00 in a research note on Friday, October 31st. Finally, Piper Sandler lifted their price objective on shares of CME Group from $296.00 to $313.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Eight investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $287.71.

CME Group Stock Up 0.2%

NASDAQ:CME opened at $281.50 on Friday. CME Group Inc. has a twelve month low of $224.62 and a twelve month high of $290.79. The firm has a market capitalization of $101.51 billion, a price-to-earnings ratio of 27.28, a price-to-earnings-growth ratio of 4.41 and a beta of 0.38. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. The stock’s 50 day moving average price is $270.60 and its two-hundred day moving average price is $272.74.

CME Group (NASDAQ:CME) last released its earnings results on Wednesday, October 22nd. The financial services provider reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.05. The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.56 billion. CME Group had a net margin of 58.84% and a return on equity of 14.61%. The firm’s revenue was down 3.0% on a year-over-year basis. During the same period last year, the business earned $2.68 earnings per share. Equities research analysts expect that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

CME Group Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Friday, December 12th will be paid a dividend of $1.25 per share. The ex-dividend date is Friday, December 12th. This represents a $5.00 annualized dividend and a dividend yield of 1.8%. CME Group’s payout ratio is currently 48.45%.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.